COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:

Coronavirus Guidance for NIH Applicants and Grantees:

Dr. Khalid Masood

Dr. Khalid Masood

Scientific Review Officer


Division of Translational and Clinical Sciences DTCS
Surgical Sciences, Biomedical Imaging & Bioengineering SBIB
Study Section:
Bioengineering, Technology and Surgical Sciences BTSS

Dr. Khalid Masood is the Scientific Review Officer for CSR’s Bioengineering, Technology, and Surgical Sciences (BTSS) Study Section in the Surgical Sciences, Biomedical Imaging and Bioengineering Integrated Review Group.

He received his Ph.D. in biochemistry from Central Drug Research Institute, India and postdoctoral training in molecular biology at the Washington University School of Medicine. He has worked as a senior staff fellow in the intramural program of NIH, patent examiner in the United States Patent and Trademark Office, and project leader at the Science Applications International Corporation for an NIMH contract. Prior to joining CSR, he was associated with the Electronic Research Administration (eRA) initiative in the Office of Extramural Research, Office of Director (OD), NIH. In the OD, he acquired knowledge of the NIH grant process, enterprise software development and management and application of information technology in science; and he developed an interest in emerging needs of NIH science administration in multidisciplinary fields. He has been involved in almost all types of grant mechanisms reviewed by CSR. Dr. Masood’s research interest has been in the molecular cloning of membrane proteins, transcriptional regulation of human glial fibrillary acidic protein (gfa) gene and molecular electrophysiological studies of recombinant N-methyl-D-aspartate (NMDA) receptor. He is the author of a number of peer-reviewed articles published in professional journals and he is the co-author of a book chapter. While at the Patent and Trademark Office, Dr. Masood granted 69 patents in the area of complex biotechnology.